SynthesisPloS one2016
Effect of Antiplatelet Therapy on Acute Respiratory Distress Syndrome and Mortality in Critically Ill Patients: A Meta-Analysis.
Synthesis in PloS one, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers, 5 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 5 syntheses or guidelines pooled it, 31 citations in OpenAlex.
- Does aspirin have an effect on risk of death in patients with COVID-19? A meta-analysis.European journal of clinical pharmacology · 2022Pooled it
- Use of aspirin in reduction of mortality of COVID-19 patients: A meta-analysis.International journal of clinical practice · 2021Pooled it
- Active prescription of low-dose aspirin during or prior to hospitalization and mortality in COVID-19: A systematic review and meta-analysis of adjusted effect estimates.International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases · 2021Pooled it
- The preventive effect of antiplatelet therapy in acute respiratory distress syndrome: a meta-analysis.Critical care (London, England) · 2018Pooled it
- Effect of antiplatelet therapy on mortality and acute lung injury in critically ill patients: A systematic review and meta-analysis.Annals of cardiac anaesthesiaPooled it
- Post-COVID Mucormycosis-Conceptual Etiology and New Treatment Options.Journal of maxillofacial and oral surgery · 2024Article
- Effect of low dose acetylsalicylic acid and anticoagulant on clinical outcomes in COVID-19, analytical cross-sectional study.Health science reports · 2022Article
- PlateletCells · 2022Review
- All-cause and in-hospital mortality after aspirin use in patients hospitalized with COVID-19: a systematic review and meta-analysis.Biology methods & protocols · 2022Review
- Nuts and bolts of COVID-19 associated coagulopathy: the essentials for management and treatment.Postgraduate medicine · 2021Review
- Aspirin Is Related to Worse Clinical Outcomes of COVID-19.Medicina (Kaunas, Lithuania) · 2021Observational
- Acetylsalicylic Acid Compared with Enoxaparin for the Prevention of Thrombosis and Mechanical Ventilation in COVID-19 Patients: A Retrospective Cohort Study.Clinical drug investigation · 2021Article
- Preventing the development of severe COVID-19 by modifying immunothrombosis.Life sciences · 2021Review
- The Emerging Threat of (Micro)Thrombosis in COVID-19 and Its Therapeutic Implications.Circulation research · 2020Review
- Pharmacological Agents Targeting Thromboinflammation in COVID-19: Review and Implications for Future Research.Thrombosis and haemostasis · 2020Review
- Gender-related efficacy of pulmonary surfactant in infants with respiratory distress syndrome: A STROBE compliant study.Medicine · 2018Observational
- Examination of biomarker expressions in sepsis-related DIC patients.International journal of general medicine · 2018Article
- Blood platelets and sepsis pathophysiology: A new therapeutic prospect in critically [corrected] ill patients?Annals of intensive care · 2017Review
- Platelets and Multi-Organ Failure in Sepsis.International journal of molecular sciences · 2017Review
- Observational
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundAntiplatelet agents are commonly used for cardiovascular diseases, but their pleiotropic effects in critically ill patients are controversial. We therefore performed a meta-analysis of cohort studies to investigate the effect of antiplatelet therapy in the critically ill.
methodsNine cohort studies, retrieved from PubMed and Embase before November 2015, involving 14,612 critically ill patients and 4765 cases of antiplatelet users, were meta-analysed. The main outcome was hospital or 30-day mortality. Secondary outcome was acute respiratory distress syndrome (ARDS) or acute lung injury (ALI). Random- or fixed-effect models were taken for quantitative synthesis of the data.
resultsAntiplatelet therapy was associated with decreased mortality (odds ratio (OR) 0.61; 95% confidence interval (CI), 0.52-0.71; I2 = 0%; P <0. 001) and ARDS/ALI (OR 0.64; 95% CI, 0.50-0.82; I2 = 0%; P <0. 001). In every stratum of subgroups, similar findings on mortality reduction were consistently observed in critically ill patients.
conclusionsAntiplatelet therapy is associated with reduced mortality and lower incidence of ARDS/ALI in critically ill patients, particularly those with predisposing conditions such as high-risk surgery, trauma, pneumonia, and sepsis. However, it remains unclear whether similar findings can be observed in the unselected and broad population with critical illness.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.